Article successfully added.

CyFlow™ CD150 FITC

CyFlow™ CD150 FITC
Alternative Name: IPO-3, SLAMF1
Antibody: Yes
Antigen: CD150
Application: Flow cytometry
Clonality: monoclonal
Clone: SLAM.4
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: FITC
Isotype: IgG1
Laser: Blue
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AW692255

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Quantity 100 tests Volume 0.4 mL Immunogen Human CD150-transfected 300.19 cells... more
Close menu
CyFlow™ CD150 FITC
Quantity100 tests
Volume0.4 mL
ImmunogenHuman CD150-transfected 300.19 cells
Background InformationCD150 (SLAM; signaling lymphocyte activation molecule) is a 70-95 kDa single chain transmembrane phosphoglycoprotein of the CD2 family. Its extracellular part contains eight potential N-glycosylation sites, and the intracellular tail contains three unique tyrosine-based motifs. These binding sites can be recognized by SH2-binding phosphatases and the adaptor proteins, such as SAP/SH2D1A or EAT-2. The SLAM family receptors are involved in leukocytes activation and contribute to the effective germinal center formation, generation of high-affinity antibody-secreting plasma cells, and memory T and B cells, thereby facilitating long-term immune response. CD150 expression is upregulated after cell activation.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| García VE, Quiroga MF, Ochoa MT, Ochoa L, Pasquinelli V, Fainboim L, Olivares LM, Valdez R, Sordelli DO, Aversa G, Modlin RL, Sieling PA: Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol. 2001 Nov 15; 167(10):5719‑24. < PMID: 11698444 > | Romero X, Benítez D, March S, Vilella R, Miralpeix M, Engel P: Differential expression of SAP and EAT‑2‑binding leukocyte cell‑surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens. 2004 Aug; 64(2):132‑44. < PMID: 15245368 > | Romero X, Zapater N, Calvo M, Kalko SG, de la Fuente MA, Tovar V, Ockeloen C, Pizcueta P, Engel P: CD229 (Ly{09} lymphocyte cell surface receptor interacts homophilically through its N‑terminal domain and relocalizes to the immunological synapse. J Immunol. 2005 Jun 1; 174(11):7033‑42. < PMID: 15905546 > | De Salort J, Sintes J, Llinás L, Matesanz-Isabel J, Engel P: Expression of SLAM (CD150) cell‑surface receptors on human B‑cell subsets: from pro‑B to plasma cells. Immunol Lett. 2011 Jan 30; 134(2):129‑36. < PMID: 20933013 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet